AC-201CR

TWi Biotechnology, Inc. · Phase 2 active Small molecule

At a glance

Generic name	AC-201CR
Sponsor	TWi Biotechnology, Inc.
Modality	Small molecule
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Proof-of-Concept Study of AC-201 Controlled-Release Tablet (CR Tablet) in Patients With Hemophilic Arthropathy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AC-201CR CI brief — competitive landscape report
AC-201CR updates RSS · CI watch RSS
TWi Biotechnology, Inc. portfolio CI